Objective NEWROFEED aims at setting a new standard of care for children suffering from Attention Deficit Hyperactivity Disorder (ADHD). ADHD@Home is the diagnosis and treatment medical device, developed by Mensia in project NEWROFEED, to achieve this goal. In order to optimise success rates, ADHD@Home is based on an EEG biomarker-based personalised medicine approach to treat ADHD children with state-of-the-art personalized Neurofeedback Training. This patient-centered solution is delivered at home, with supervision by ADHD specialists. As an efficacious alternative to treatment by psychoactive medication, the expected clinical outcomes include normalized social behaviour and improved school performance.ADHD@Home delivers physiological lasting normalization of brain activity, using the child’s endogenous neuronal plasticity, to resolve his or her attention and hyperactivity problems. Its unique technology and design enable it to achieve two critical clinical objectives:1. To identify the root cause of the ADHD for a given child by quantifying, in real-time, deviations in EEG oscillation biomarkers allowing the clinician to select and adjust the Neurofeedback protocols.2. To deliver the personalized Neurofeedback protocols on an affordable and user-friendly device, enabling optimal training at home under remote medical supervision. This clinical breakthrough is made possible by Mensia’s cloud-based real time quantitative EEG analysis technology. ADHD@Home will be validated for efficacy in the NEWROFEED Clinical Trial. This will pave the way for a successful commercial launch in 2018 to deliver on our promise of efficacious physiological treatment for millions of ADHD children. Thanks to NEWROFEED, Mensia will become a world leader in the field of EEG-based personalised treatment of Central Nervous System disorders; capitalizing on the clinical success of its ADHD@Home device that will generate 65M€ in cumulative revenues by 2022. Fields of science natural sciencesbiological sciencesneurobiologymedical and health scienceshealth sciencespublic healthmedical and health sciencesclinical medicinepsychiatrymedical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsmedical and health scienceshealth sciencespersonalized medicine Programme(s) H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being Main Programme H2020-EU.2.1.3. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Advanced materials H2020-EU.3.1.3. - Treating and managing disease Topic(s) PHC-12-2015 - Clinical research for the validation of biomarkers and/or diagnostic medical devices Call for proposal H2020-SMEInst-2014-2015 See other projects for this call Sub call H2020-SMEINST-2-2015 Funding Scheme SME-2 - SME instrument phase 2 Coordinator MENSIA TECHNOLOGIES Net EU contribution € 3 600 632,50 Address PLACE DU GRANIER 35571 CHANTEPIE France See on map SME The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed. Yes Region Bretagne Bretagne Ille-et-Vilaine Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost € 3 600 632,50